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Serum FHR1 binding to necrotic-type cells activates
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Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil
cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a
dominant trigger of inflammation: human serum factor H-related protein FHR1. In vitro, this
protein selectively binds to necrotic cells via its N-terminus; in addition, it binds near necrotic
glomerular sites of AAV patients and necrotic areas in atherosclerotic plaques. FHR1, but not
factor H, FHR2 or FHR3 strongly induces inflammasome NLRP3 in blood-derived human
monocytes, which subsequently secrete IL-1β, TNFα, IL-18 and IL-6. FHR1 triggers the
phospholipase C-pathway via the G-protein coupled receptor EMR2 independent of com-
plement. Moreover, FHR1 concentrations of AAV patients negatively correlate with glo-
merular filtration rates and associate with the levels of inflammation and progressive disease.
These data highlight an unexpected role for FHR1 during sterile inflammation, may explain
why FHR1-deficiency protects against certain diseases, and identifies potential targets for
treatment of auto-inflammatory diseases.
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Cellular stress is a spontaneous event triggered by injury orinfection and is a characteristic of inflammatory diseases,such as anti-neutrophil cytoplasmic antibody-associated
vasculitis (AAV)1 and atherosclerosis (AS)2, 3. Necrotic cells act
as unmodified damage-associated molecular patterns (DAMPs),
which activate innate immunity and, together with membrane-
anchored molecules, recruit and activate the inflammasome in
immune cells, such as monocytes or neutrophils4. Pro-
inflammatory cytokine IL-1β can be released via a cell death
process (pyroptosis) which is a highly inflammatory event5, or via
hyperactivated cells where cells maintain viability6. In both cases
pore forming gasdermin is involved7. Secretion of IL-1β, IL-6, IL-
8, and TNFα recruits phagocytic leukocytes and activates stem
cells to replace dead cells8. However, sustained immune responses
can seriously damage host tissues and thus cause various dise
AAV is a systemic autoimmune disease characterized by
autoantibodies specific for proteinase 3 (PR3) and myeloper-
oxidase (MPO) expressed by neutrophils. Histopathology
commonly shows pauci-immune crescentic glomerulone-
phritis1. Activation of the alternative complement pathway
amplifies the recruitment, priming, and activation of neu-
trophils, thereby creating a self-amplifying inflammatory loop
that results in destructive and necrotizing vascular injury. In
AAV, small- and medium-sized blood vessels, such as those in
the kidney and lung, are infiltrated by immune cells and
eventually destroyed9.
AS is a chronic vascular disease and especially in its form of
coronary artery disease the most common cause of death in
developed countries. Lipid deposits form in regions of arteries
with disturbed blood flow, leading to formation of atherosclerotic
plaques comprising necrotic cells, which trigger sterile inflam-
mation. Rupture of plaques can cause myocardial infarction or
stroke. Patients with AS show high activation of the inflamma-
some 3 (NLRP3) in the aorta2, 3.
Complement senses DAMPs and microbe-associated
molecular patterns (MAMPs). Complement activation
destroys microbes and induces phagocytosis and clearance
mechanisms also of damaged and dead human cells. Factor H
(FH), the main regulator of the alternative complement
pathway, is crucial in the protection of self surfaces from the
damaging effects of complement10. In contrast to these well
studied vital functions of FH, the central function of the factor
H related protein FHR1 remains unclear to date. FHR1
comprises five short consensus repeats (SCRs) but lacks the
regulatory domains found in FH. In vitro assays revealed that
FHR1 inhibits the terminal complement pathway in the
absence of FH11. In addition, FHR1 competes with FH to
regulate FH inhibitory activity12, 13. However, the composition
and concentration of FHR1 suggest a more specific role in
immunity. The N-terminal SCRs, named SCR1–2, within
FHR1 are 36 and 45% identical to FH/SCR6–7, respectively,
and contain a hybridization domain13, 14. The C-terminal
SCR3–5 domains are 100/97, 100 and 98% identical to FH/
SCR18–20, respectively, and bind C3b, C3d, and heparin11.
FHR1 circulates in serum as homodimers and forms hetero-
dimers with FHR214, which are contained in so-called FH-
related proteins associated lipoprotein particles (FALPs)15.
Genetic deletion of a chromosomal fragment comprising
CFHR3-CFHR1 genes (ΔFHR1/3) confers protection against
IgAN16 and AMD17, but susceptibility to systemic lupus ery-
thematosus (SLE)18 and atypical HUS19. The reason for these
opposing associations between FHR1 and different diseases is
still unclear, although likely ascribed to an as-yet-unknown
function of FHR1. Here, we show FHR1 binding to necrotic-
type cells and thereby inducing sterile inflammation, which is
different to pyroptotic induced necroinflammation20.
Results
FHR1 induces pro-inflammatory cytokine secretion. In a pre-
vious study we demonstrated that FH binds to oxidized lipid
deposits and inhibits complement activation and inflammatory
responses21. To investigate whether FHR1 also modulates
inflammation, we coated microtiter plates with FHR1 and incu-
bated it with freshly isolated human peripheral blood monocytes
in normal human serum (NHS) with or without lipopoly-
saccharide (LPS). Cytokine concentrations in the supernatant
were measured after 20 h. The results showed that FHR1 alone
strongly induced release of the pro-inflammatory cytokine IL-1β
from monocytes, and increased LPS-triggered secretion of IL-1β
(Fig. 1a). By contrast, immobilized FHR2, FHR3, FHL-1, FH, and
BSA failed to induce IL-1β production (Fig. 1b, c). FHR1-induced
IL-1β in a dose-dependent manner (0.6–5 µg ml−1) (Fig. 1d) as
early as 3 h after the start of co-incubation (Fig. 1e). Inflamma-
tory responses were triggered by the C-termini of FHR1/SCR3–5
and also FH/SCR19–20, as demonstrated in a similar assay. The
N-terminus (SCR1-2) of FHR1 failed to induce IL-1β (Fig. 1f).
Immobilized FHR1 did not trigger pyroptosis22 as seen by no
release of the enzyme lactate dehydrogenase (LDH) and full cell
viability, measured via cell titer blue assay. (Fig. 1g). Similar to
FHR1, immobilized mouse FHR1 homolog FHRB (Supplemen-
tary Fig. 1a) induced IL-1β secretion by mouse monocytes
(Fig. 1h) in mouse serum. In parallel with IL-1β induction, FHR1-
triggered secretion of pro-inflammatory cytokines IL-18, TNFα,
and IL-6 (Fig. 1i–k), but not IL-8 (Supplementary Fig. 1b). It also
inhibited secretion of the anti-inflammatory cytokine IL-10 by
LPS-stimulated monocytes (Fig. 1l). Similar to IL-1β, TNFα was
released by monocytes after 3 h of co-incubation with immobi-
lized FHR1 (Fig. 1m).
Because FHR1 circulates in human serum, we next measured
its pro-inflammatory function in a fluid phase. The microtiter
plate surface was blocked and monocytes, FHR1, and NHS were
added. In this setting, FHR1 had no effect on IL-1β (Fig. 2a) or
IL-10 (Supplementary Fig. 1c) production. Thus, immobilization
of FHR1 was necessary to trigger the pro-inflammatory response.
Furthermore, pro-inflammatory function of FHR1 was lost
without NHS, heat-inactivated or EDTA-containing NHS (Fig. 2b,
and Supplementary Fig. 1d). FHR1-induced IL-1β release at low
NHS concentrations (0.25%); which increased at higher NHS
concentrations (Fig. 2c). In summary, surface-bound (not free)
FHR1 induces secretion of IL-1β and inhibits IL-10 release by
monocytes in the presence of active NHS.
FHR1-induced inflammation is independent of complement.
Having shown that FHR1 requires active NHS to trigger secretion
of IL-1β and to inhibit IL-10 production by monocytes, we asked
whether the complement system is essential for its pro-
inflammatory function. We found that FHR1 increased secretion
of IL-1β and blocked IL-10 release in the presence of C3-depleted
or C3- or C5-inhibited NHS (Fig. 3a, and Supplementary Fig. 2a)
and with blocked CR3 or C3aR (Supplementary Fig. 2b). Neither
C3 nor C5 was involved in FHR1 function. Blocking the classical-
and the lectin-induced complement pathways (EGTA-treated or
C1q-depleted NHS) or the alternative pathway (factor B- or
P-depleted NHS) did not inhibit FHR1 activity (Fig. 3b, c, and
Supplementary Fig. 2c, d). Thus, FHR1-mediated inflammation is
independent of the complement pathways.
FHR1 activates NLRP3 via the EMR2 receptor. To find out how
FHR1 induces the production and release of IL-1β23, we first
inhibited NF-κB or caspase-1 and found that FHR1-mediated
release of IL-1β was completely blocked (Fig. 3d, e). FHR1-
induced transcription of pro-IL-1β and TNFα exclusively in the
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Fig. 1 FHR1 induces inflammation. a Immobilized FHR1 induces IL-1β secretion by monocytes and increases IL-1β production by LPS-stimulated monocytes
in the presence of NHS. b, c In contrast, FHR2, FHR3, FHL-1, FH, and BSA fail to induce IL-1β secretion. d Immobilized FHR1 reduces IL-10 secretion and
increases IL-1β secretion by LPS-stimulated monocytes in a dose-dependent manner. e Immobilized FHR1 triggers IL-1β release from monocytes as early as
3 h after the start of incubation. f FHR1 SCR3-5 and FH SCR19-20, but not FHR1 SCR1-2, trigger IL-1β release by monocytes exposed to ΔFHR1/3 NHS.
g Monocytes remain healthy after incubation with FHR1, as demonstrated by very low release of LDH (left) and full cell viability (right). Maximum LDH
release (maxLDH) was measured after lysis of cells and lost viability with Nigericin sodium salt or Triton X-100 treatment via cell titer blue (CTB) assay.
h FHRB induces IL-1β release by mouse monocytes exposed to mouse serum. Treatment with NLRP3 inhibitor (MCC950) inhibits FHRB-induced IL-1β
release. i Immobilized FHR1 induces secretion of IL-18, j TNFα and k IL-6, and l reduces IL-10.m Immobilized FHR1 triggers release of TNFα from monocytes
as early as 3 h after incubation. Data in a–m represent the mean ± SEM. of three to five independent experiments with different donor cells. *p≤ 0.05, **p≤
0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
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Fig. 2 FHR1-induced inflammation depends on immobilization and NHS. a Unbound FHR1 fails to increase secretion of IL-1β by monocytes. b In the absence
of NHS or in the presence of heat-inactivated (h.i.) and EDTA-inactivated NHS (EDTA), immobilized FHR1 does not induce IL-1β secretion. c FHR1 induces
secretion of IL-1β upon exposure to 0.25% NHS. Increasing the concentration of NHS increases IL-1β release. Data in a–c represent the mean ± SEM. of
three to four independent experiments with different donor cells. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10766-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2961 | https://doi.org/10.1038/s41467-019-10766-0 | www.nature.com/naturecommunications 3
presence of NHS, as shown by increased RNA transcription in
monocytes (Supplementary Fig. 2e, f). However, inhibiting TLR2,
TLR4, TLR6, CD14, CD36, RAGE, Dectin 1, or Fc-receptors did
not interfere with FHR1-induced IL-1β secretion (Supplementary
Fig. 2g–j and Supplementary Table 1). Thus, FHR1 in presence of
active NHS induces the inflammasome via a specific receptor-
mediated signaling pathway.
Caspase-1 is activated by NLRP1, NLRP3, NLRC4, AIM2 or
Pyrin24. Incubating monocytes with a specific NLRP3 inhibitor
completely inhibited FHR1- and FHRB-mediated IL-1β release,
thereby confirming involvement of NLRP3 in the activation
process (Fig. 3f, and Fig. 1h). To identify the FHR1-triggered
pathway, we measured reactive oxygen species (ROS) as ROS
release or cathepsin B trigger formation of the NLRP3
inflammasome. FHR1 failed to induce ROS release by monocytes
(in contrast to the microbe C. albicans) (Supplementary Fig. 2k).
Similarly, inhibiting K+ efflux25 and cathepsin B did not affect
FHR1-induced IL-1β production (Supplementary Fig. 2l). How-
ever, IL-1β release is blocked by phospholipase C (PLC) inhibitors
(Fig. 3g, and Supplementary Fig. 2m) and substantially reduced
by inhibition of Gβγ, the subunit of G protein-coupled receptor
(GPCR) (Fig. 3h).
As many pro-inflammatory receptors induce PLC and Ca2+,
we examined the FHR1 signaling pathways by RNA sequencing
in monocytes derived from four different donors upon incubation
with FHR1 and NHS for 4 h. We identified 522 monocytic genes
upregulated in response to FHR1 (gene ontology enrichment
analysis: ‘immune response’, ‘cellular response to TNF’, ‘neu-
trophil chemotaxis’, ‘cellular response to IL-1’, and ‘signal
transduction and inflammatory response’ (Fig. 4a, b). 35
upregulated genes (6.7%) were inflammation related, including
NF-kB, NLRP3, and calcium-signaling pathways (KEGG) (Fig. 4c,
d). Gene associated disease (GAD) analysis confirmed that
patterns of upregulated genes by FHR1 are found in chronic renal
failure, hypertension, myocardial infarction, atherosclerosis,
stroke, and blood pressure (Fig. 4e). Furthermore, FHR1
upregulated the GPCR EMR2/ADGRE2, which was previously
described to induce an inflammatory response via PLC and
intracellular Ca2+ release26. Indeed, inhibition of EMR2 receptor
completely blocked FHR1-induced IL-1β release (Fig. 4f). Sub-
sequent interaction assays confirmed binding between recombi-
nant EMR2 and FHR1 by ELISA and surface plasmon resonance
technique (Fig. 4g, h). In summary, FHR1 activates PLC via
EMR2, which stimulates Ca2+ release from the endoplasmic
reticulum and activates NLRP3, followed by activation of caspase-
1, which then cleaves pro-IL-1β to IL-1β27 (Fig. 4i).
FHR1 binds to necrotic cells and induces inflammation. Having
shown that surface-coated FHR1 induces the NLRP3 inflamma-
some, we asked when FHR1 mediates this function. Healthy or
necrotic human endothelial cells (HUVECs) were incubated with
FHR1 or purified FH and binding was analyzed by flow cyto-
metry. FHR1, but not FH, bound to necrotic HUVECs and nei-
ther molecule bound to healthy cells (Fig. 5a, and Supplementary
Fig 3a). Also, FHR1 did not bind to living or early apoptotic
(induced by staurosporine) cells, but to necrotic (staurosporine),
necroptotic (induced by Z-VAD-FMK, TNFα and Cyclohex-
imide) and pyroptotic cells (induced by Nigericin sodium salt)
(Supplementary Fig. 3b–d). Similar to FHR1, FHRB bound to
necrotic mouse alveolar macrophages, but not to healthy cells
(Fig. 5b, and Supplementary Fig. 3e). Thereby FHR1 bound to
distinct spots on necrotic cells, which had lost cell surface
integrity as seen by reduced wheat germ agglutinin (WGA)









































































































































































Fig. 3 FHR1 activates NLRP3 in monocytes via the PLC pathway. a Immobilized FHR1 increases secretion of IL-1β in LPS-treated monocytes exposed to C3-
depleted, C3-inhibited (Compstatin), or C5-inhibited (Eculizumab) NHS. b FHR1 stimulates secretion of IL-1β by EGTA-treated or C1q-depleted NHS, which
blocks the classical (CP) and lectin pathways (LP) activation, respectively, as well as in c factor B (FB)- or factor P (FP)-depleted NHS (in which the
alternative pathway (AP) is inhibited). d IL-1β induction by FHR1 is blocked when NF-κB is inhibited by BAY 11-7085. e IL-1β secretion is blocked by a
caspase-1 inhibitor (VX-765), f by a NLRP3 inhibitor (MCC950), or g by a PLC inhibitor (U73122). h Blocking Gβγ subunit of GPCRs with Gallein reduces
IL-1β induction by FHR1 by about 65% after 4 h incubation. Data in a-h represent the mean ± SEM. of three independent experiments with cells from
different donors. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
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NHS, both FH and FHR1 from NHS bound to necrotic but not to
living cells (Fig. 5d). In this case, binding of FH was explained by
its interaction with C3b on the surface; by contrast, FHR1 bound
to cells in the presence/absence of C3b. When bound to C3b
(Supplementary Fig. 3f) via SCR3–511, FHR1 lost the ability to
induce release of IL-1β (Fig. 5e). However, FHR1 alone attached
to necrotic cells via the N-terminal SCR1–2 domains, as shown by
flow cytometry (Fig. 5f, and Supplementary Fig. 3g). Therefore we
concluded that FHR1 domains SCR3–5 trigger inflammation
when FHR1 is bound to necrotic cells.
To examine whether necrotic cell surface-bound FHR1 also
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Fig. 4 FHR1 binds to G protein-coupled receptor EMR2. a Genes differentially expressed in monocytes exposed for 4 h to FHR1 and NHS. b Biological
processes involved in FHR1 induction (GO classification). c Inflammatory genes and d signaling pathways induced in monocytes by FHR1. e Upregulated
genes in response to FHR1 show significant overlap with upregulated genes in certain diseases. f IL-1β induction by FHR1 is blocked by inhibition of EMR2
(αEMR2). g Recombinant EMR2 binds to FHR1 but not to gelatine (gel.) in ELISA. h The bond between EMR2 and FHR1 is in a dose-dependent manner
shown via surface plasmon resonance technique. i Schematic overview of FHR1-induced IL-1β generation pathway in monocytes. Data in a–h represent the
mean ± SEM of three to four independent experiments with cells from different donors. **p≤ 0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
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FHR1 and incubated them with monocytes in presence of NHS.
FHR1 bound to necrotic cells triggered a >four-fold increase of
IL-1β release by monocytes when compared with necrotic cells
alone (Fig. 5g). As expected, incubating necrotic cells with
monocytes in NHS containing FHR1-triggered IL-1β release.
The IL-1β level dropped by about 60% when monocytes were
incubated in FHR1 deficient (ΔFHR1/3) NHS (Fig. 5h).
Reconstitution of ΔFHR1/3 serum with FHR1 resulted in a
strong release of IL-1β; this was not the case for FH (Fig. 5i). To
confirm FHR1 interaction with EMR2, FHR1/EMR2 complexes
were determined by proximity ligation assay (PLA) in an
ex vivo whole blood model system with necrotic cells. FHR1/
EMR2 complexes were identified on monocytes that were in
contact with necrotic cells or cell debris when incubated in
FHR1 sufficient but not in ΔFHR1/3 blood (Fig. 5j). In contrast,
FHR1 did not form complexes with TGFβRI (Supplementary
Fig 3h).
FHR1 binds to MDA-LDL and increases inflammation.
Malondialdehyd-modified low-density lipoproteins (MDA-
LDL) are a marker of oxidative stress and are produced by
damaged and necrotic cells28. FHR1 binds to MDA-LDL, but
not to LDL or BSA (Fig. 6a) in a dose-dependent manner
(Fig. 6b,c). Binding of FHR1 to MDA-epitopes expressed by
necrotic HUVECs was confirmed using PLA (Fig. 6d). Similar
to necrotic cells, FHR1 also bound to MDA-LDL via SCR1–2
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Fig. 5 FHR1 binds to necrotic cells and triggers IL-1β release by monocytes. a, FHR1, but not FH binds necrotic HUVECs, as shown by flow cytometry.
b FHRB binds to necrotic but not healthy mouse alveolar macrophages, FHRB antiserum was used for flow cytometry. c FHR1 (green) binds to necrotic
cells. DNA (blue) is stained with DAPI and membrane (red) with WGA. Scale= 10 µm. d FHR1 and FH from NHS bind to necrotic, but not to healthy cells.
One representative western blot of three is shown. e FHR1 bound to C3b does not induce IL-1β release by monocytes. f FHR1 SCR1–2 binds to necrotic
HUVECs. g FHR1 bound to necrotic HUVECs triggers IL 1β in monocytes. h IL-1β release in response to necrotic HUVECs is reduced in ΔFHR1/3 NHS
compared to NHS. i Reconstitution of FHR1 in ΔFHR1/3 NHS increased IL-1β release by monocytes. FH has no effect. j Complexes (red) of FHR1 (on
necrotic cells) with EMR2 receptor (on monocytes) in whole blood. Total picture fluorescence intensity of single cells (n= 14 for FHR1/3, n= 10 for
ΔFHR1/3) were analyzed using unpaired two-tailed t-test. Data in a–i represent the mean ± SEM of three to four independent experiments with different
cell donors. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
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by monocytes by about 40% (Fig. 6f). Thus, FHR1 is a sensor of
necrotic cell surfaces and induces inflammation.
FHR1 binds to necrotic cells in vivo. We next asked whether
FHR1 is targeted to specific necrotic cells in vivo. Necrosis and
inflammation are hallmarks of AAV and AS29, 30. Therefore,
attachment of FHR1 to glomeruli in AAV patients and to
atherosclerotic plaques in AS was examined by immunohis-
tochemistry (IHC). Kidney tissue sections from patients diag-
nosed with AAV and glomerulonephritis were stained for FHR1.
Granular positivity is seen for FHR1 in parts of the glomerular
matrix that are in proximity to fibrinoid necrosis31 but not on
healthy tissue (Fig. 7a). Weak signals were detected for C3c and
FHR2 in these areas (Supplementary Fig. 4a). In AS plaques on
surfaces are formed by lipid accumulation and oxidation and
contain necrotic cells. Staining of human plaques in the human
artery and heart valve revealed specific binding of FHR1 to the
plaques, but not to healthy cells close to the plaques (Fig. 7b). In
contrast to FHR1, FHR2 showed low binding to the heart valve
and is found predominantly in the intima of the artery (Fig. 7b).
Furthermore, FHR1/EMR2 but no FHR1/TGFβRI complexes
were identified in tissue section from FHR1 sufficient AAV and
AS patients but not in sections from ΔFHR1/3 AAV patients
(Fig. 7c, and Supplementary Fig. 4b and 4c). In summary, FHR1/
EMR2 complexes are formed in AAV and AS tissues.
ΔFHR1/3 NHS from AAV patients show low IL-1β and CRP.
FHR1 binds to necrotic cells and induces inflammation. To
determine the relevance of this process, we measured IL-1β
concentrations in AAV patients. In a cohort of 314 AAV patients,
11 had ΔFHR1/3 deficiency, which is consistent with the
frequency in the normal healthy Caucasian population32 (Sup-
plementary Fig. 4d). AAV patients harboring FHR1/3 or ΔFHR1/
3 are of similar age and gender (Supplementary Fig. 4e, f). When
we compared IL-1β serum concentrations according to the pre-
sence/absence of FHR1, we found very low amounts of IL-1β in
AAV patients with ΔFHR1/3 (0.6 ± 0.1 pg ml−1), similar to those
in healthy controls (0.4 ± 0.1 pg ml−1). By contrast, in patients
with active FHR1 significantly higher IL-1β concentrations were
detected (1.4 ± 0.3 pg ml−1, p < 0.05, unpaired t-test with Welch’s
correction) (Fig. 7d). IL-1β serum concentrations did not directly
correlate with ANCA antibodies, in contrast to C-reactive protein
(CRP) (Supplementary Fig. 4g, h). Therefore, CRP concentra-
tions, which can substantially increase in response to IL-6, were
analyzed in serum samples of AAV patients and revealed sig-
nificant lower amounts in patient samples with ΔFHR1/3 (5.4 ±
0.4 mg dL−1) in comparison to patients harboring FHR1/3 (36.9
± 3.5 mg dL−1, p < 0.001, unpaired t-test with Welch’s correction)
(Fig. 7e). In addition, we measured exact FHR1 concentrations in
the serum samples by ELISA. AAV patients showed significantly
increased FHR1 concentrations (69.8 ± 3.7 μg mL−1) compared to
healthy individuals (26.5 ± 2.3 μg mL−1, p < 0.0001, unpaired t-
test with Welch’s correction) (Fig. 7f). As the previously pub-
lished FHR1 concentration in healthy donors was 70–100 μg mL
−1 11, we tested different protein sources for standard curves in
the used ELISA kit and indeed, the FHR1 concentration in NHS
varied by a factor of 1–3.5 (25–95 μg mL−1). Also the IL-1β
concentration increased with FHR1 serum concentrations (p=
0.0598, Spearman correlation) in AAV patients without immu-
nosuppressive therapy (Supplementary Fig. 4i). Furthermore, the
estimated glomerular filtration rate (eGFR) negatively correlated















































































































Fig. 6 FHR1 binds to MDA-LDL on necrotic cells. a FHR1 binds to MDA-LDL, but not to LDL or BSA. b FHR1 binds to MDA-LDL in a dose-dependent manner
as shown by ELISA and c surface plasmon resonance. d FHR1 binds to MDA epitopes on necrotic cells, as demonstrated by proximity ligation assay. Red
dots denote FHR1-MDA complexes. DNA is stained with DAPI (blue). Control= one antibody. e FHR1 binds with its N-terminus FHR1 SCR1-2 to MDA-LDL.
f FHR1 bound to MDA-LDL, but not LDL, increases IL-1β release by monocytes. Data in a–f represent the mean ± SEM. of three to four independent
experiments with different cell donors. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 (unpaired two-tailed t-test)
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correlation) (Fig. 7g) and accordingly relapse (Fig. 7h) and death
rates (Supplementary Fig. 4j) increased with growing FHR1
concentrations. PR3/MPO antibody positive patients with
ΔFHR1/3 showed reduced fresh fibrinoid necrosis and cellular
crescents compared to FHR1/3 harboring patients (Supplemen-
tary Fig. 4k, l). Altogether the data demonstrate an in vivo
influence of FHR1 on inflammation and progression of the
disease.
Inhibition of FHR1. As inflammation is reduced by 50% in
ΔFHR1/3 NHS we asked whether FHR1 antibodies would
decrease the inflammatory response in NHS. Monoclonal FHR1 F
(ab)2 fragments applied to NHS reduced the IL-1β release of
monocytes by about 50%, thus to the same level as in ΔFHR1/3
NHS (Fig. 7i). In conclusion, inhibition of the FHR1 N-terminus
by a monoclonal antibody reduced FHR1-mediated inflammation
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FHR1 forms homodimers and heterodimers with FHR213.
When SCR1–2 of FHR1 was immobilized and incubated with
NHS, we found that serum-derived FHR1 bound to FHR1
SCR1–2. Addition of increasing amounts of FHR2 out-competed
serum-bound FHR1 (Fig. 7j). By contrast, replacement of FHR1
was not observed when the dimerization motif of FHR2 was
mutated (FHR2DM) (Fig. 7k, and Supplementary Fig. 4m).
Addition of FHR2, but not FHR2DM, to the serum reduced the
concentration of monocytes derived IL-1β by about 50% (Fig. 7l,
m). These results demonstrate that FHR2 inhibits FHR1 activity
by forming heterodimers, and that FHR2 may restrict FHR1-
mediated inflammation.
Discussion
Inflammation is a fundamental cellular response to harmful sti-
muli such as pathogens, trauma, and necrosis. In these cases,
transient inflammation leads to clearance and healing, thereby
maintaining cellular homeostasis. However, sustained immune
responses can cause auto-inflammation, in which innate immune
responses play the primary pathophysiological role33. Here, we
identified a human inducer of inflammation, FHR1, which binds
to oxidized LDL on necrotic-type human cell surfaces and
strongly induces the NLRP3 inflammasome in monocytes via
GPCR EMR2 exposed to NHS (Fig. 8). FHR1 deficiency, which is
present in 4–7% of Caucasians32, leads to a substantial reduction
in IL-1β secretion (about 50%) in response to necrosis. Accord-
ingly, AAV patients harboring ΔFHR1/3 show low IL-1β as well
as CRP serum concentrations and are better regarding glomerular
necrosis and relapses compared to patients with FHR1. This is
confirmed by reduced necrotic inflammation (about 50%) upon
addition of monoclonal FHR1 F(ab)2 fragments to NHS in vitro.
These data demonstrate a dominant function of FHR1 in
necrotic-type surface triggered inflammation, which may explain
why ΔFHR1/3 protects against auto-inflammatory diseases such
as IgAN16 and AMD17. Both diseases are characterized by cell
stress and pathological inflammatory processes with involvement
of the NLRP3 inflammasome34.
Immobilized FHR1 (as well as the murine homolog FHRB), but
not FHR2, FHR3, FH, or the spliced variant of FH, FHL-1,
induces the NLRP3 inflammasome in monocytes, which subse-
quently secrete pro-inflammatory cytokines. IL-1β and TNFα are
central cytokines in immune cell communication and activation
and as such recruit innate immune cells to the site of infection
and cell damage. IL-6 triggers CRP release and IL-18 is respon-
sible for generating interferon-γ (IFN-γ) and for increasing
the cytolytic activity of natural killer cells and T-cells. To induce
IL-1β, FHR1 binds to oxidized lipids on necrotic cells via its
N-terminal domain, linking the pro-inflammatory features of
oxidized lipids35, 36 to NLRP3 activation in monocytes. Thereby
FHR1 does not induce cell death such as pyroptosis, necroptosis
or necrosis in monocytes and cytokines are secreted via intact
lipid bilayers as previously described for hyperactivated macro-
phages7. The benefit of cell survival is that IL-1β together with
secreted factors can act immunomodulatory. Upon binding,
FHR1 likely changes its conformation such that the C-terminus
becomes exposed and mediates the inflammatory response. As
both the C-terminal domains of FHR1 (SCR3–5) and FH
(SCR19–20) induce IL-1β secretion by monocytes, this suggests
that the C-terminal domains of both proteins are hidden or
protected when they are circulating in human plasma. Indeed,
FHR1 is present primarily in so-called FALPs15, which may shield
the inflammatory activity of FHR1. Similarly, FH with a circular
Fig. 7 In vivo functions of FHR1. a In AAV, FHR1 attaches to necrotic cells (arrow), surrounding fresh fibrinoid necrotic lesions in the glomerulus (asterisk)
but not in healthy tissue (discontinued arrow) (n= 79). Glomeruli derived from ΔFHR1/3 AAV patients (n= 9) lack FHR1 signals. Bars= 20 µm. b FHR1
(red) signal is found on macrophages and damaged smooth muscle cells in atherosclerotic plaques in human heart valve (n= 4, bars= 50 µm) and arteries
(n= 6, bars= 200 µm) of AS patients. FHR2 staining is located to the intima of arteries. MGTE=Masson Goldner Trichrome Elastica. c EMR2/FHR1
complexes in kidney biopsies of FHR1/3, but not of ΔFHR1/3 AAV patients as shown by PLA assay. DNA is stained with DAPI. Twelve pictures of 3 FHR1/3
and seven pictures of 2 ΔFHR1/3 were analyzed (unpaired two-tailed t-test). Bar= 10 µm. d Serum IL 1β and e CRP with FHR1/3 compared to ΔFHR1/3
AAV patients (d, e unpaired two-tailed t-test with Welch’s correction and Kruskal–Wallis Test). f FHR1 concentrations in healthy individuals and AAV
patients (unpaired two-tailed t-test, Welch’s correction). g Estimated glomerular filtration rate (eGFR) decreases (Spearman correlation) and h percentage
of relapses of AAV patients increases with growing FHR1 concentrations. i Addition of F(ab)2 fragments of a FHR1 antibody to NHS reduces monocytic IL-
1β to a level comparable to inflammation in ΔFHR1/3 NHS triggered by necrotic cells. j Natural FHR1 monomers bound to FHR1 SCR1–2 and are replaced by
FHR2, but k not by dimerization mutant FHR2DM. l FHR1 on necrotic cells in ΔFHR1/3 NHS increases IL-1 β, which is reduced by FHR2 but not m by
FHR2DM. Data in a–b show box and whiskers from min to max with mean ± SEM. (Wilcoxon Signed Rank test) and data in i-m represent the mean ± SEM.

























Fig. 8 Overview. FHR1 binds to necrotic-type cells and induces inflammation in monocytes in NHS. Accumulation of necrotic-type cells recruits FHR1, which
over-activates monocytes and induces inflammatory disorders
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structure was previously described, in which the C-terminus is
folded back37. Like FH, FHR1 can bind to the TED domain in
C3b via the C-terminal SCR domains38. When bound to C3b,
FHR1 lacks pro-inflammatory activity, confirming the C-
terminus as the main inflammatory actor in FHR1. In sum-
mary, FHR1 can activate the NLRP3 inflammasome in immune
cells by binding directly via its N-terminus to oxidized lipids on
necrotic cells.
FHR1 activates the NLRP3 inflammasome in monocytes via
the PLC and Ca2+ activation pathways. RNAseq data derived
from FHR1-induced monocytes suggested involvement of GPCR
EMR2/ADGRE2, which induces inflammatory responses in
macrophages26, 39. Specific inhibition of EMR2 confirmed FHR1
action via this receptor on monocytes. Activation of NLRP3 via
binding of FHR1 to EMR2 is dependent on an additional so far
unknown serum signal. However, EMR2 has been shown to be
cleaved by a self-catalyzed process characteristic of an autopro-
teolytic reaction40 which might be triggered by the serum signal.
EMR2 involvement in FHR1 function is supported by the fact
that EMR2 is highly expressed in foamy macrophages in
atherosclerosis41, 42 and to correlate with disease severity and
mortality in patients with cirrhotic liver disease39.
Necrosis plays an important role in AAV and treatment of
inflammation through aggressive immunosuppression is the
established therapy43, 44. Also, in AS recent trials follow inhibition
of inflammation45. ΔFHR1/3 was detected in 3.5% of AAV cases
and IL-1β concentrations were not increased in these ΔFHR1/3
AAV patients; indeed, the concentrations were low and comparable
to those measured in healthy controls. Moreover, the acute phase
protein and inflammation marker CRP, which increases in response
to IL-6, was significantly lower (p < 0.001, unpaired t-test with
Welch’s correction) in ΔFHR1/3 AAV samples compared to
patients harboring FHR1. Noteworthy patients with ΔFHR1/3 had
less fibrinoid necrosis and less cellular crescends compared to
FHR1/3 harboring patients. In AAV patients the overall FHR1
concentration was much higher compared to healthy individuals.
The FHR1 serum concentration associated with the progression of
the disease as they negatively correlated with the glomerular fil-
tration rates and with increased relapses and death rates. Also,
FHR1 concentrations in AAV patients without immunosuppressive
therapy showed increased IL-1β concentrations. These results
confirm the pro-inflammatory function of FHR1 in AAV, which is
characterized by forms of necrosis and inflammation, including
NLRP3 activation, elevated IL-1β serum concentrations29, and local
accumulation of immune cells46, 47.
Genetically, ΔFHR1/3 protects against IgA nephropathy16 and
AMD48, 49 and is a reported risk for atypical hemolytic uremic
syndrome (aHUS)50 and SLE18, as well as rheumatoid arthritis51
(all of which are associated with inflammation). Thus, it is
tempting to speculate that in AMD and IgAN FHR1 is a major
driver of inflammation and that ΔFHR1/3 protects against these
diseases by reduced inflammation. The pathological mechanisms,
however, underlying these diseases are more complex. That said,
patients with these chronic diseases need to be evaluated to
support the pro-inflammatory role of FHR1 and that symptoms
arise from established lesions.
Most importantly, our data provide evidence that direct
intervention with FHR1 function inhibits inflammation in human
diseases like AAV to reduce progression and even induce
regression. Therefore, targeting FHR1 or members of the FHR1
pathway like EMR2 presents as a promising therapeutic approach
for future intervention to control inflammation.
Methods
Cell growth conditions. Human umbilical vein endothelial cells (HUVEC, ATCC
CRL-1730) were grown in DMEM (Lonza) with FBS (10%, PAA), ultraglutamine
(1%, Lonza) and gentamicin sulfate (Lonza) at 37 °C and CO2 (5%). Murine
alveolar MH-S macrophages (ATCC CRL-2019) were grown in RPMI 1640
(Lonza) supplemented with heat-inactivated FBS (10% FBS), sodium-pyruvate
(1 mM, Lonza), ultraglutamine (1%) and gentamicin sulfate (50 mgmL−1) at 37 °C
and CO2 (5%). THP-1 cells (DSMZ, ATCC 16) were maintained in RPMI
1640 supplemented with FBS (10%), ultraglutamin (2 mM) and gentamicine sulfate
at 37 °C and CO2 (5%). U-937 cells (ATCC CRL-1593.2) were cultered in RPMI
1640 supplemented with FBS (10%) and gentamicin sulfate at 37 °C and CO2 (5%).
Cells were authenticated and tested for mycoplasma contamination by ATCC,
passaged every second day until passage 30. Normal human serum (NHS) was
prepared from FHR1/3 sufficient as well as FHR1/3 deficient (ΔFHR1/3 NHS)
blood derived from healthy volunteers, as determined by PCR52 and Western blot
analyses. After coagulation blood was centrifuged (10 min, 2000×g, 4 °C), and NHS
kept frozen in aliquots at −80 °C. C. albicans cph1Δ/efg1Δ53, 54, which cannot form
hyphae, was grown overnight in YPD medium (D glucose (2%), peptone (1%),
yeast extract in H2O (5%) at room temperature.
Isolation of human monocytes. Biocoll (14 mL, Biochrom) was overlayed by a
mixture of DPBS (5 mL, Lonza) and buffy coat (30 mL), derived from healthy male
donors. After centrifugation (20 min, 550×g) the PBMC layer was washed with
DPBS (5 min, 160×g). Biocoll and wash steps were repeated twice. Pellet was
resuspended in IMDM (25 mL, Thermo Scientific) overlayed on Percoll (46%, GE
Healthcare Life Sciences) in IMDM and centrifuged (20 min, 550×g). From PBMC
layer monocytes were selected according to the protocol of the human Monocyte
Isolation Kit II (MiltenyiBiotec). Monocyte experiments were performed in com-
plete medium composed of 10% FBS and gentamicin sulfate in IMDM (Thermo
Fisher Scientific).
Isolation of murine bone marrow-derived macrophages. All animal experiments
were approved by the appropriate institutional and governmental committees for
animal welfare and procedures conducted according to guidelines of the local
Animal Use and Care Committee and the National Animal Welfare Laws (Zuch-
trahmenantrag 02-05/16). Bone marrow cells were isolated from 10–19 weeks-old
male mice (C57BL/6) and differentiated to macrophages according to the protocol
of Francke et al.55. Blood was collected from 10–25 weeks old mice (C57BL/6) by
cardiac puncture in hirudin S-Monovette (Sarstedt). Serum was collected by cen-
trifugation (2000×g, 10 min, 4 °C) and stored at −20 °C.
Proteins. Recombinant FHR1, FHR1 SCR1-2, FHR1 SCR3-5, and FHR2 were
expressed in Pichia pastoris11, 56. Recombinant FHL-1, FHR3, and FH SCR19-20
were expressed in baculovirus expression system57–59. BSA was purchased by
AppliChem and factor H (FH) from Complement Technology. Full length FHRB
(pCMV3-insert-Myc, Sino Biological Inc.) was restricted by Kpn1/Xba1, cloned
into piCZαB (Invitrogen) expression vector and expressed in P. pastoris. Polyclonal
rabbit FHRB antiserum was generated (Davids Biotechnologie GmbH). FHR2
dimerization mutant was generated by in vitro mutagenesis of the CFHR2 con-
taining piCZα expression vector60 using Quick Change Multi Site-Directed
Mutagenesis Kit (Agilent Technologies) and the primer CAAGTTCCTACAGGG
GAAGTTTTCTCTTACTACTGTGAGAGAATTTTGTGTCTCCTTCAAAATCC
T. Mutagenesis was confirmed by sequencing. The His-tagged protein was
expressed in P. pastoris strain X33 and purified by nickel chelate affinity chro-
matography. All proteins were evaluated by silver gel and western blot analyses.
Cytokine experiments. FHR1, FHR2, FHR3, FHL1, FH, and BSA (each 50 µL of
5 µgmL−1) were coated on a High Binding ELISA plate (Sarstedt) for 1 h at 37 °C.
Afterwards proteins were incubated with 1 × 105 monocytes/well in complete medium
with or without 10% NHS and with or without stimulation with 5 ngmL−1 LPS. After
20 h incubation at 37 °C and CO2 (5%) cytokines in the supernatant were measured
according to the protocol of the human cytokine ELISA kits: IL-1β, IL-6 and IL-10
(ThermoFisherScientific), IL-8 (Peprotech), IL-18 (R&D Systems) and TNFα (Bio-
Legend). The absorbance was measured by microplate reader (TECAN, Safire2). For
dose-dependent studies 50 µL of 0.6, 1.25, 2.5, and 5 µgmL−1 of FHR1 were used for
coating. For time dependent studies FHR1 or BSA were incubated with monocytes
for 0, 15, 30, 60, 90, 120, 180, and 240min. Fragments FHR1 SCR1-2, FHR1 SCR3-5
or FH SCR19-20 (each 50 µL of 5 µgmL−1) were coated and incubated with
monocytes in ΔFHR1/3 NHS (10%) or with LPS-treated monocytes in NHS (10%).
FHRB (5 µgmL−1) or DPBS were coated to a microtiter plate and incubated with
mouse monocytes (1 × 105) in normal mouse serum (10%) and 5% CO2 with or
without MCC950 (10 µM, InvivoGen) for 20 h at 37 °C. IL-1β was measured in the
supernatant using a mouse IL-1β kit (BioLegend). Testing FHR1 activity in serum,
plates were blocked with BSA prior incubation of monocytes with FHR1 (5 µgmL−1)
or BSA in serum with or without LPS. In another assay NHS was heat inactivated 30
min at 56 °C or inactivated by addition of EDTA (10mM, Roth). To measure dose
dependency, monocytes were incubated in 0, 0.1, 0.25, 0.5, 0.75, 1, 2.5, 5, 7.5, 10%
NHS in IMDM without FBS.
For inhibition studies: C1q, C3, factor B and factor D depleted NHS was
purchased by Complement Technology. C3 inhibition was performed with
Compstatin (15 μM, Tocris Bioscience), C5 with Eculizumab (50 nM, Alexion
Pharmaceuticals), CR3 by Simvastatin (20 μM, Sigma-Aldrich) and C3aR by
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trifluoroacetate salt (TAS) (200 nM, Sigma-Aldrich). Classical and lectin pathways
were inhibited with EGTA (10 mM, Sigma-Aldrich). NF-κB was blocked with BAY
11-7085 (30 µM, Sigma-Aldrich), TLR2 with pAb hTLR-2 (10 µg m−1L, InvivoGen,
LOT T2S-38-01), TLR4 with LPS-RS Ultrapure (22.2 μg mL−1, InvivoGen), TLR6
with pAb hTLR-6 (10 µg mL−1, InvivoGen, LOT T6S-36-01), Dectin 1 with WGP
Soluble (1 μg mL−1, InvivoGen), FcR with FcR Blocking Reagent (2 µLmL−1,
MiltenyiBiotec), CD14 with FITC hCD14 antibody (10 μg mL−1, BioLegend, LOT
B187006), CD36 with mAb hCD36 (5 μg mL−1, Hycultec, LOT 17003M1114-B)
and the human RAGE receptor with RAGE mouse anti-human clone 176902
(10 µg mL−1, R&D Systems, LOT ICW0217021). The NLRP3-inflammasome was
blocked with MCC950 (10 µM, Invivogen), Caspase-1 with VX-765 (50 μg mL−1,
InvivoGen), K+ efflux with Glybenclamide (25 μg mL−1, InvivoGen), Cathepsin
B with Cathepsin B inhibitor (1 μM, Santa Cruz Biotechnology) and PLC with
U73122 (10 µM, Abcam) or 1,10-Phenanthroline monohydrate (200 µM,
AppliChem). Gβγ subunit of GPCR was blocked with Gallein (10 μM, Tocris) and
EMR2 receptor via EMR2 antibody (10 μg mL−1, R&D Systems, Cat. Nr. AF4894,
LOT CCOS011805A). IL-1β was measured after 4 h incubation. The IL-1β response
to FHR1 bound to C3b was determined after C3b (5 µg mL−1) was coated for 1 h at
37 °C. C3b was blocked with blocking buffer I (200 µL) for 1 h at 37 °C and
incubated with FHR1 (10 µg mL−1) for 2 h at 37 °C. Each step was followed by
washing four times with DPBS 0.05% Tween 20. Afterwards monocytes (1 × 105)
were added and incubated for 20 h at 37 °C.
Healthy and necrotic (treated 35 min at 63 °C) HUVECs (each 1 × 105) were
incubated with FHR1 or BSA (each 10 µg) for 20 min at 37 °C. After washing with
DPBS (1% BSA), HUVECs (1.5 × 104) were incubated with monocytes (6 × 104) in
CM with NHS (10%) for 20 h at 37 °C and CO2 (5%). The supernatant was
collected for IL-1β measurement. In addition, monocytes (1 × 105) were incubated
with necrotic HUVECs (5 × 104) in NHS or ΔFHR1/3 NHS (each 10%) in CM.
Afterwards ΔFHR1/3 NHS was reconstituted with FHR1 (0, 5, 10, 50, 75 or 100 µg
mL−1) or FH (10 or 100 µg mL−1).
F(ab)2 fragments of monoclonal FHR1 antibody11 were generated with Pierce
Mouse IgG1 Fab and F(ab)2 micro Preparation Kit (Thermo Scientific) according
to the provided protocol. Monocytes (1 × 105) were incubated with necrotic cells
(5 × 104) and ΔFHR1/3 NHS (5%) or NHS (10%) and FcR blocker (2 μLmL−1)
with or without addition of F(ab)2 (25 μg mL−1) for 20 h at 37 °C.
To investigate the influence of FHR2, monocytes (1 × 105) were incubated with
necrotic HUVECs (5 × 104) in ΔFHR1/3 NHS (5%) in CM with addition of BSA
(3 μg) or FHR1 (3 μg) with or without FHR2 or FHR2DM (each 3 μg). FHR1
binding to low-density lipoprotein (LDL) and Malondialdehyde-modified LDL
(MDA-LDL) (both Cell Biolabs) was performed by coating LDL or MDA-LDL
(each 5 µg mL−1) for 1 h at 37 °C, blocked with blocking buffer I (200 µL,
AppliChem) for 1 h at 37 °C and incubated with FHR1 (10 µg mL−1) for 2 h at
37 °C. Incubation with monocytes was followed by cytokine measurement as
described above.
RNA purification and analysis. FHR1 (50 µL of 5 µg mL−1) or BSA was immo-
bilized and incubated with monocytes (1 × 105) in CM with or without NHS (10%)
for 4 h at 37 °C. RNA was extracted using total RNA purification kit (NORGEN)
and converted to cDNA by High Capacity RNA-to-cDNA Kit (Thermo Fisher
Scientific). Quantitative PCR (StepOnePlus™ Real-Time PCR System, Thermo
Fisher Scientific) was performed with cDNA derived from total RNA (0.25 ng
according to NanoDrop ND-1000 Spectrophotometer (peqlab Biotechnologie),
PerfeCTA SYBR Green Fast mix Low Rox (Quanta Bio) and primers ACTB for-
ward 5′GCTAAGTCCTGCCCTCATTT′3, ACTB reverse 5′GTACAGGTCTTTG
CGGATGT′3, IL-1β forward CTCTCACCTCTCCTACTCACTT′3, IL-1β reverse
TCAGAATGTGGGAGCGAATG′3, and TNFα forward 5′CCAGGGACCTCTCT
CTAATCA′3, and TNFα reverse 5′TCAGCTTGAGGGTTTGCTAC′3. Actin beta
was used as endogenous control. Data were analyzed with Expression Suite Soft-
ware version 1.1 and StepOne™ Software v2.3. RNA from FHR1 treated monocytes
from four different donors were mixed (total 3.4 μg) and sequenced by LC Sciences.
Data were analyzed using DAVID 6.7 and Panther 9.0 software.
LDH measurement and cell titer blue assay. Immobilized FHR1 (50 µL of 5 µg
mL−1) in triplicate was incubated with monocytes (1 × 105) in IMDM with NHS
(0.25%) for 20 h at 37 °C in CO2 (5%). For LDH measurement, after 19 h lysis
buffer (10 µL) was added for 45 min at 37 °C. Supernatants (50 µL) were incubated
with the reaction mixture of Pierce LDH Cytotoxicity Assay Kit (50 μL, Thermo
Scientific) for 30 min at RT. The reaction was stopped with stop solution (50 µL)
and absorbance was measured at 490 nm. In the cell titer blue (CTB) assay,
supernatant was removed after 20 h, cells washed and incubated with 100 μl CTB
solution (Promega) for 6 h at 37 °C and absorbance was measured at 570–600 nm.
To induce pyroptosis monocytes were treated with Nigericin (20 μM, Santa Cruz
Biotechnology) for 20 h or Triton-X-100 (0,1%, Sigma-Aldrich) for 3 min.
ROS measurement. FHR1 (50 µL of 5 µg mL−1), BSA or DPBS were coated to a
microtiter plate for 1 h at 37 °C. Proteins were incubated with monocytes (1 × 105)
in CM with or without 10% NHS. As positive control monocytes (1 × 105) were
incubated with C. albicans cph1Δ/efg1Δ (5 × 104). After 20 h incubation at 37 °C
and CO2 (5%) CellROX™ Deep Red Reagent (2 µLmL−1, Thermo Scientific) was
added and the absorbance measured at Ex/Em 480/515-550 nm.
Protein binding to HUVECs. Binding of FHR1 to healthy and necrotic HUVECs
(each 3 × 105) was determined by incubation with FHR1, FH or BSA (each 10 µg)
for 20 min at 37 °C in DPBS (1% BSA). Cells were stained with mAb C02 (1:500)61
and Alexa Fluor 488 donkey anti-mouse IgG (1:500, Invitrogen, LOT 1820538)
with Viability Dye eFluor® 780 (1:10000, eBioscience), each for 20 min at 4 °C in
DPBS (1% BSA). Between each step the cells were washed two times with DPBS
(1% BSA) and fluorescence was measured via flow cytometry (gated according to
FSC/SSC).
FHR1 fragments SCR1-2 and SCR 3-5 (each 50 µl of 60 µg mL−1) were
incubated with necrotic cells (5 × 105) for 30 min at 37 °C in DPBS (1% BSA). The
cells were stained using α-Penta His (1:500, QUIAGEN) and Alexa 488 donkey
α-mouse (1:500, Invitrogen, LOT 1820538), Viability Dye eFluor® 780 (1:10.000)
each for 20 min at 4 °C in DPBS (1% BSA). Between each step cells were washed
two times with DPBS (1% BSA) and fluorescence measured by flow cytometry
(gated according to FSC/SSC).
Binding of FHR1 and FH from NHS was evaluated by incubating healthy or
necrotic HUVECs (each 1 × 106) in 50% NHS (diluted in DPBS) for 30 min at
37 °C. After extensive washing, cells were lysed 30 min on ice in lysis buffer (70 µL)
pH 7.4 with Triton X-100 (1% v/v) (Sigma) and Protease Inhibitor Cocktail
(Roche) in DPBS. Roti®-Load 2 (Roth) 13.5 µL was added to each sample (40 μL)
and heated for 10 min at 95 °C. Samples (40 µl) were separated via SDS-PAGE and
immunoblotted using polyclonal FHR1 antiserum62 (1:1.000) and HRP-conjugated
α-rabbit antibody (1:1000, Dako, LOT 00087384). FHR1 (10 µg mL−1) was again
bound to necrotic HUVECs (45 min at 65 °C) for 30 min at 37 °C and cells were
stained with polyclonal FHR1 antiserum62 (1:1.000) for 30 min at RT. Cells were
incubated with Alexa FluorTM488 donkey anti-rabbit IgG (1:500, Invitrogen, LOT
1796375), DAPI (10 µg mL−1, Sigma), and WGA Texas Red (1:100, Invitrogen) for
30 min at RT. Between each step, cells were washed twice with 1% BSA in DPBS.
Images were captured using LSM 710 (Zeiss) with ZEN 2009 software. Uncropped
blot is provided in the Source Data file.
Protein binding to necrotic-type cells. Apoptosis was induced by treatment of
HUVEC cells with staurosporine (0,5 μg ml−1, o. n., Sigma-Aldrich). Afterwards
cells (4.5 × 105) were incubated with BSA, FHR1 (20 μg ml−1) or NHS (50%) for
20 min at 37 °C. The cells were stained using a monoclonal mouse FHR1 anti-
body11 (1:500), followed by Alexa 488 donkey α-mouse (1:500, Invitrogen, LOT
1820538), Viability Dye eFluor® 780 (1:10.000) and FITC Annexin V (1:20, Bio-
Legend, LOT B223857) each for 20 min at 4 °C. Necroptosis was induced by
treatment of PMA preincubated (1 μg ml−1, o. n., Sigma-Aldrich) U937 cells with
Z-VAD-FMK (50 μM, Santa Cruz Biotechnology) for 1 h at 37 °C, followed by
TNFα (50 ng ml−1, gibco) and Cycloheximide (50 μg ml−1, biomol) for 4 h 20 min
at 37 °C. Pyroptosis was induced by treatment of PMA preincubated THP1 cells
with Nigericin sodium salt (20 μM, Santa Cruz Biotechnology) for 2 h 30 min at
37 °C. Afterwards necroptotic cells (3.5 × 105) or pyroptotic cells (3 × 105) were
incubated with BSA or FHR1 (50 μg ml−1) for 30 min at 37 °C and stained with
mAb C02 (1:500)61 and Alexa Fluor 647 anti-mouse IgG (1:500, Cell Signaling
Technology, LOT 14) with Viability Dye eFluor® 780 (1:10.000) and FITC Annexin
V (1:20, BioLegend, LOT B223857) each for 20 min at 4 °C in DPBS (1% BSA).
Between each step the cells were washed two times with DPBS (1% BSA) and
fluorescence was measured via flow cytometry (gated according to FSC/SSC and
VD/Annexin).
Proximity ligation assay. FHR1 (20 μg mL−1) was incubated with necrotic
HUVECs (45 min at 65°) at 37 °C for 60 min with shaking at 700 rpm. Washed
cells (5 × 105) were seeded onto Poly-L-lysine (Sigma-Aldrich) coated diagnostic
slides, type PTFE (Carl Roth) and incubated with polyclonal rabbit FHR1 anti-
serum62 (1:500) and monoclonal mouse MDA-LDL antibody E01463 (1:100).
Control cells were incubated with polyclonal rabbit FHR1 antiserum62 (1:500) and
mouse IgM ĸ Isotype Ctrl antibody (Biolegend, LOT B214463) (1:50). PLA assay
was performed according to manufacturer’s protocol provided with Duolink In Situ
Red Starter Kit Mouse/Rabbit (Sigma-Aldrich). Images were captured using LSM
710 with ZEN 2011.
FHRB binding to mouse alveolar macrophages. Healthy as well as necrotic
(30 min at 63 °C) mouse alveolar macrophages (each 5 × 105) were incubated with
FHRB or BSA (each 10 μg) for 20 min at 37 °C followed by rabbit FHRB antiserum,
generated to the recombinant protein (1:500, Supplementary Fig. 1a) and Alexa 647
goat α-rabbit (1:500, Invitrogen, LOT 1893813) together with Viability Dye eFluor®
780 (1:10.000), each for 20 min at 4 °C. Between each step cells were washed two
times in DPBS with 1% BSA. FHRB binding was analyzed by flow cytometry (gated
according to FSC/SSC).
FHR1 binding to lipids and proteins. LDL, MDA-LDL (both Cell Biolabs) or BSA
(each 5 µg mL−1) were coated for 1 h at 37 °C, blocked with 200 µL blocking buffer
I for 1 h at 37 °C and incubated with 30 µg mL−1 FHR1 2 h at RT, polyclonal FHR1
antiserum11 (1:1000) in Cross Down buffer (AppliChem) as well as HRP-labeled
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polyclonal anti-rabbit IgGs (Dako, LOT 00087384) 1 h at RT. All steps included
3–5 wash steps with DPBS 0.05% Tween 20 (Sigma-Aldrich). Afterwards TMB
(50 μL, eBioScience) was added and reaction was stopped with H2SO4 (2M, Roth).
The absorbance at 450 nm was measured with a microplate reader. MDA-LDL
(5 μg mL−1) was coated and after blocking FHR1 (0, 1, 2.5, 5 or 10 µg mL−1) were
incubated for 2 h 37 °C. The kinetics of FHR1 binding to MDA-LDL (5 μg mL−1)
were measured via surface plasmon resonance technique using (Biacore 3000).
MDA-LDL was immobilized to a sensor chip (CM5) using a standard amine-
coupling and FHR1 (250 – 2.000 nM) or FHR1 SCR 1-2 or SCR 3–5 (each 10 μg
mL−1) in PBS injected with a flow rate of 5 μLmin−1 at 25 °C.
FHR1 binding to C3b was analyzed by coating C3b or FHR1 (each 5 µg mL−1)
to a microtiter plate for 1 h at 37 °C, blocked with blocking buffer I (200 μL) for 1 h
37 °C and incubated with FHR1 (10 μg mL−1) for 2 h at 37 °C. The ELISA was
continued as described for MDA-LDL. Binding of recombinant human EMR2 to
FHR1 was determined by immobilizing FHR1 (10 μg mL−1) or gelatin to a
microtiter plate o. n. at 4 °C. Proteins were blocked with blocking buffer for 1 h at
37 °C, incubated with EMR2 (R&D Systems) or BSA (30 μg mL−1) for 2 h at 37 °C,
and binding detected with polyclonal EMR2 antiserum (0.5 μg mL−1, R&D
Systems, LOT CCOS011807A) in Cross Down Buffer and HRP-labeled polyclonal
anti-sheep IgGs (Dako, LOT 00082910), each 1 h at RT. All steps included 3–5
wash steps with DPBS 0.05% Tween 20. Afterwards TMB (50 μL, eBioScience) was
added and reaction was stopped with H2SO4 (2 M, Roth). The kinetics of FHR1
binding to EMR2 was measured via surface plasmon resonance technique using a
Biacore 3000 instrument as described above. Different concentrations of FHR1
(125–2.000 nM) in PBS were used.
Ex vivo whole blood model. Blood was collected from healthy volunteers with
FHR1 and ΔFHR1/3. Serum was separated from blood by centrifugation (2.000 × g,
10 min). RBCs were removed from whole blood by water lysis and centrifugation
(2000×g, 10 min). Whole blood cells (7.5 × 105) were added to 12 mm Poly-l-lysine
coated coverslips in a 24-well plate in RPMI medium (Lonza) supplemented with
heat-inactivated FCS (10%) and ultra-glutamine 1 (2 mM, Lonza) and incubated
for 2 h at 37 °C and 5% CO2 to allow to adhere to the coverslips. Other whole blood
cells (7.5 × 105) from the same donor were incubated at 65 °C for 45 min to gen-
erate necrotic cells. The necrotic cells were incubated in NHS (100%) from the
same donor and collected by centrifugation (2.000×g). Necrotic cells were resus-
pended in medium along with 10% NHS and were added to coverslips for adhering
to the surface. Whole blood cells, necrotic cells and NHS from one donor were
incubated for 1.5 h and reaction stopped by addition of paraformaldehyde (4%,
Roth). Cells were permeabilized with saponin (0.1%, Sigma-Aldrich). Fc receptors
of the cells were blocked with FcR Blocking Reagent (Miltenyi Biotec) and Duolink
blocking solution (Sigma-Aldrich). Cells were then treated with monoclonal mouse
FHR1 antibody11 (1:200) and polyclonal rabbit anti-EMR2 antiserum (Abcam,
LOT GR152070-7) (1:200) or TGFβRI antibody (Sigma Aldrich, 211126) (1:200).
PLA assay was performed according to manufacturer’s protocol provided with
Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma-Aldrich). Images were
captured using LSM 710 equipped with ZEN 2011. Fluorescent intensity of the
images was calculated using Fiji software.
Replacement of FHR1 by FHR2 or FHR2DM. FHR1 SCR 1–2 (5 μg mL−1) was
immobilized on a microtiter plate over night at 4 °C, incubated with NHS (5%) in
DPBS for 1 h at 37 °C, and FHR2 or FHR2DM (0, 1, 5, or 15 μg mL−1) was added
to each probe. FHR1 was detected by incubation with monoclonal antibody C1861
(1:1000) for 1 h at RT and FHR2DM with monoclonal FHR2 antibody60 and HRP-
conjugated anti-mouse IgG (1:1000, Dako, LOT 20013032). All steps included 3–5
wash steps with DPBS, 0.05% Tween 20.
Patients. Patients with ANCA-associated necrotizing glomerulonephritis (n=
314) as diagnosed by kidney biopsies and PR3 and MPO antibodies and AS
patients with acute coronary artery disease awaiting coronary artery bypass surgery
were included in the cohort study. Blood and tissue samples from patients were
collected and analyzed in this study. In addition, blood samples from healthy
donors (n= 55) were collected as controls.
Immunohistochemistry. Atherosclerotic plaques were obtained from patients
with high-grade aortic sclerosis with concomitant ascending aorta replacement
during coronary artery bypass grafting. Atherosclerotic plaques consisted mainly
of the diseased area resulting from the surgical excision. Kidney biopsies were
taken from AAV patients. Human coronary plaques and kidney biopsies were
segmented in blocks of 3–4 mm, fixed in formalin overnight, decalcified in 0.5 M
EDTA (pH 7.2) and embedded in paraffin (FFPE)64. Tissue sections (1 μm) were
stained for presence of FHR1, C3c, and FHR2 by pre-incubating the sections
with a protease solution for 30 min at 40 °C. Subsequently the sections were
incubated with monoclonal FHR1 antibody11 (1:40.000), C3c antibody (1:3.000,
Dako, LOT 00055806) or monoclonal FHR2 antibody60 overnight at 4 °C. As
detection antibodies AffiniPure Rabbit Anti-Mouse IgG (H+ L) (Jackson
ImmunoResearch, LOT 136143) and Alkaline Phosphatase (APAAP complex)
(ALPL) (Monoclonal Antidbody MyBioSource, LOT 2E14317) were used.
Stained slides were developed using ZytochemPlus/POLAP100 (Zytomed),
incubated with polymer 1 and 2 and rinsed in between with PBS. Slides were
stained in fuchsin naphthol As-Bi phosphate substrate mixture for 30 min and
for nuclear counterstaining in hemalaun (Mayer) for 1 min and quantified using
ImageJ or ZEN software. For PLA assays Paraffin-embedded sections of human
atherosclerotic plaques or AAV kidney biopsies were deparaffinized by placing
them consecutively in Roticlear (Carl Roth), 100% ethanol, and 95% ethanol.
Sectioned tissues were boiled in 10 mM Na citrate buffer (pH 6.5) for antigen
retrieval and blocked with normal serum block (Biolegend) and FcR Blocking
Reagent diluted in antibody diluent (Roth). Tissues were then treated with
monoclonal mouse anti-FHR1 antibodies11 (1:200) and polyclonal rabbit anti-
EMR2 antiserum (Abcam, LOT GR152070-7) (1:200) or TGFβRI antibody
(Sigma Aldrich, 211126) (1:200) diluted in antibody diluent. For antibody
control tissues were treated with exclusively rabbit anti-EMR2 antiserum
(1:200). PLA assay was performed according to the manufacturer’s protocol
provided with Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma-Aldrich).
Images were captured using LSM 710 equipped with ZEN 2011.
Analysis of serum samples. IL-1β serum levels were determined by high sensitive
IL-1ß Kit (Thermo Fisher Scientific), anti-MPO-antibodies (ORG 519 Orgentec),
anti-PR3-antibodies (ORG 618, Orgentec) by ELISA, and FHR1 concentration by
Human CFHR1 ELISA Kit (RayBiotech) according to the protocol provided by the
manufacturers. CRP levels were measured by module C701 (Cobas8000). All
samples below CRP detection limit of 5 mg dL−1 were defined as 5 mg dL−1.
Presence of FHR1 in NHS samples was determined by Western Blot analysis and
absence confirmed by PCR19. Roti®-Load 2 (2.5 μL, Roth) was added to NHS (1 μL)
diluted in DPBS (10 μL) and samples were separated by SDS-PAGE. Immuno-
blotting was performed with polyclonal FH antiserum (1:7.500, CompTech, LOT
#4) and HRP-conjugated goat antibody (1:2.500, Dako, LOT 00073984).
Ethics. After informed consent was obtained, patient data, blood, and tissue
samples were collected according to the guidelines of the local ethics committees
(PV3162, PV4068, and PV5657 University Hospital Eppendorf, Hamburg and
5071-02/17 Friedrich-Schiller University, Jena) and the Guidelines of the World
Medical Association Declaration of Helsinki. Patient’s data are summarized in
Supplementary Table 2.
Statistical analysis. Significant differences between two groups were analyzed
using the unpaired two-tailed Student’s t-test of GraphPad Prism 5 for Windows.
AAV and AS patients were analyzed using the unpaired two-tailed t-test with
Welch’s correction and Kruskal–Wallis Test. Semi quantitative IHC was analyzed
using Wilcoxon Signed Rank test. Correlation between IL-1β/CRP, IL-1β/ANCA,
IL-1β/FHR1, and FHR1/eGFR were analyzed using Spearman correlation test.
Values of *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 were considered as statistically
significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data generated for this study have been deposited at the Gene Expression Omnibus
(GEO) under accession code GSE119025. The source data underlying Figs. 1–3, 4f–h, 5a,
b,d–j, 6a–c,e,f, 7, and Supplementary Figs. 1, 2, 3b–d, f, h, and 4d–m including all
uncropped gels and blots are provided as a Source Data file.
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